CoChat

Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy

Open access

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Significance: In mitophagy, damaged mitochondria are targeted for disposal by the autophagy machinery. PARKIN promotes signaling of mitochondrial damage to the autophagy machinery for engagement, and PARKIN mutations cause Parkinson’s disease, possibly because damaged mitochondria accumulate in neurons. Because regulation of PARKIN abundance and the impact on signaling are poorly understood, we performed a genetic screen to identify PARKIN abundance regulators. Both positive and negative regulators were identified and will help us to further understand mitophagy and Parkinson’s disease. We show that some of the identified genes negatively regulate PARKIN gene expression, which impacts signaling of mitochondrial damage in mitophagy. This link between transcriptional repression and mitophagy is also apparent in neurons in culture, bearing implications for disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1711023115

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. endoGFP-PARKIN cells display PARKIN level-dependent pUb accumulation. (A) Clonal JumpIN Cas9+ cells carrying a stable transgene driving GFP-PARKIN expression from 4.5 kb of the endogenous PARK2 promoter (endoGFP-PARKIN; green) or not (GFP-negative parental cells; gray) were assessed for GFP-dependent fluorescence by flow cytometry. (B and C) endoGFP-PARKIN cells display near-complete CRISPR/Cas9-mediated GFP-PARKIN depletion. Cells expressing either an SCR sgRNA or one of two different PARK2-specific sgRNAs (#i, #ii) were assessed for GFP-dependent fluorescence (B) and GFP-PARKIN protein levels (C) 8 or 15 d postinfection. (D) Comparison of GFP-PARKIN protein levels in endoGFP-PARKIN cells to endogenous PARKIN. Protein lysates from stable cell pools expressing either an SCR sgRNA or a PARK2-specific sgRNA (#i) were assessed by WB analysis using indicated antibodies. (E) PARKIN-dependent pUb accumulation in JumpIN cells treated with CCCP. endoGFP-PARKIN cells or parental JumpIN cells expressing PARK2-specific or SCR sgRNAs for 8 d were treated with 10 µM CCCP or vehicle for 6 h, and lysates probed with the antibodies indicated. (F) PARKIN-dependent MFN2 ubiquitination and degradation in parental cells (Upper) or endoGFP-PARKIN cells (Lower). WB analysis using indicated antibodies of stable cell pools expressing PARK2-specific or SCR sgRNAs treated with A/O for the time indicated. WB, Western blot.
Fig. 1. endoGFP-PARKIN cells display PARKIN level-dependent pUb accumulation. (A) Clonal JumpIN Cas9+ cells carrying a stable transgene driving GFP-PARKIN expression from 4.5 kb of the endogenous PARK2 promoter (endoGFP-PARKIN; green) or not (GFP-negative parental cells; gray) were assessed for GFP-dependent fluorescence by flow cytometry. (B and C) endoGFP-PARKIN cells display near-complete CRISPR/Cas9-mediated GFP-PARKIN depletion. Cells expressing either an SCR sgRNA or one of two different PARK2-specific sgRNAs (#i, #ii) were assessed for GFP-dependent fluorescence (B) and GFP-PARKIN protein levels (C) 8 or 15 d postinfection. (D) Comparison of GFP-PARKIN protein levels in endoGFP-PARKIN cells to endogenous PARKIN. Protein lysates from stable cell pools expressing either an SCR sgRNA or a PARK2-specific sgRNA (#i) were assessed by WB analysis using indicated antibodies. (E) PARKIN-dependent pUb accumulation in JumpIN cells treated with CCCP. endoGFP-PARKIN cells or parental JumpIN cells expressing PARK2-specific or SCR sgRNAs for 8 d were treated with 10 µM CCCP or vehicle for 6 h, and lysates probed with the antibodies indicated. (F) PARKIN-dependent MFN2 ubiquitination and degradation in parental cells (Upper) or endoGFP-PARKIN cells (Lower). WB analysis using indicated antibodies of stable cell pools expressing PARK2-specific or SCR sgRNAs treated with A/O for the time indicated. WB, Western blot.CC BY-NC-ND · PubMed Central
Fig. 2. A genome-wide CRISPR/Cas9 screen identifies genes affecting cellular GFP-PARKIN level. (A) Workflow of the screening process. endoGFP-PARKIN cells were transduced with a lentiviral sgRNA library targeting 18,360 genes with an average of five sgRNAs per gene in independent replicates (n = 2). Infection was performed at a low MOI to achieve one sgRNA/cell. After selection, the least (GFP-low) and most (GFP-high) GFP-fluorescent cells (25%) were FACS-sorted on day 8 and day 15 postinfection, and genomic DNA was recovered from the unsorted and sorted pools and subjected to NGS for sgRNA counting. sgRNA count data were processed to assess missing sgRNAs as a measure of library coverage as well as replicate correlation. Count ratios for individual sgRNAs from GFP-low and -high are expressed as fold-change values and plotted against gene-level probability-based RSA scores. (B) Analysis of GFP-low and -high samples reveals candidate hit genes. (Upper) Day 8 analysis. (Lower) Day 15 analysis. y axis: RSA scores; x-axis: sgRNA fold-changes in GFP-low vs. GFP-high (second strongest sgRNA). Candidate hit genes selected for individual confirmation are colored, and genes selected for WB analysis are labeled (Fig. 3B) (green labeling for time-point–specific genes). (C) Hypergeometric gene-set enrichment analysis was performed using the top 500-scoring genes of either the GFP-low or -high analysis. The P values denoting the significance of the enrichments from day 8 are plotted against day 15 (−log10). FDR, false discovery rate; gDNA, genomic DNA; MOI, multiplicity of infection; NGS, next-generation sequencing; WB, Western blot.
Fig. 2. A genome-wide CRISPR/Cas9 screen identifies genes affecting cellular GFP-PARKIN level. (A) Workflow of the screening process. endoGFP-PARKIN cells were transduced with a lentiviral sgRNA library targeting 18,360 genes with an average of five sgRNAs per gene in independent replicates (n = 2). Infection was performed at a low MOI to achieve one sgRNA/cell. After selection, the least (GFP-low) and most (GFP-high) GFP-fluorescent cells (25%) were FACS-sorted on day 8 and day 15 postinfection, and genomic DNA was recovered from the unsorted and sorted pools and subjected to NGS for sgRNA counting. sgRNA count data were processed to assess missing sgRNAs as a measure of library coverage as well as replicate correlation. Count ratios for individual sgRNAs from GFP-low and -high are expressed as fold-change values and plotted against gene-level probability-based RSA scores. (B) Analysis of GFP-low and -high samples reveals candidate hit genes. (Upper) Day 8 analysis. (Lower) Day 15 analysis. y axis: RSA scores; x-axis: sgRNA fold-changes in GFP-low vs. GFP-high (second strongest sgRNA). Candidate hit genes selected for individual confirmation are colored, and genes selected for WB analysis are labeled (Fig. 3B) (green labeling for time-point–specific genes). (C) Hypergeometric gene-set enrichment analysis was performed using the top 500-scoring genes of either the GFP-low or -high analysis. The P values denoting the significance of the enrichments from day 8 are plotted against day 15 (−log10). FDR, false discovery rate; gDNA, genomic DNA; MOI, multiplicity of infection; NGS, next-generation sequencing; WB, Western blot.CC BY-NC-ND · PubMed Central
Fig. 3. Confirmation of primary screen hit genes. (A) High correlation of individual sgRNA performance in the primary pooled screen and individual confirmation experiments. Day 8 fold-changes (log2) for the strongest scoring sgRNAs in the primary screen were plotted against fold-changes (log2) as determined in Fig. S3. Pearson’s correlation and corresponding significance values are shown. n = 108. (B) Lysates from endoGFP-PARKIN cells individually expressing the strongest scoring sgRNAs for 24 hits for 15 d were assessed for GFP-PARKIN levels and for CRISPR/Cas9 editing efficiencies by TIDE. (C) Fifty-three positive and negative regulators subjected to functional gene network analysis. Top and bottom 25 hits confirmed by flow cytometry on day 8 (Fig. S3), together with additional hits validated in B were used as input query for STRING database analysis of known and predicted protein-protein interactions (physical and functional). STRING gene annotations were used to group hits. The highest confidence cutoff was used (STRING V10.0). Large spheres, protein structure known; small spheres, no known protein structure. db, database; eff., efficiency; exp., experimentally; nd, not determined.
Fig. 3. Confirmation of primary screen hit genes. (A) High correlation of individual sgRNA performance in the primary pooled screen and individual confirmation experiments. Day 8 fold-changes (log2) for the strongest scoring sgRNAs in the primary screen were plotted against fold-changes (log2) as determined in Fig. S3. Pearson’s correlation and corresponding significance values are shown. n = 108. (B) Lysates from endoGFP-PARKIN cells individually expressing the strongest scoring sgRNAs for 24 hits for 15 d were assessed for GFP-PARKIN levels and for CRISPR/Cas9 editing efficiencies by TIDE. (C) Fifty-three positive and negative regulators subjected to functional gene network analysis. Top and bottom 25 hits confirmed by flow cytometry on day 8 (Fig. S3), together with additional hits validated in B were used as input query for STRING database analysis of known and predicted protein-protein interactions (physical and functional). STRING gene annotations were used to group hits. The highest confidence cutoff was used (STRING V10.0). Large spheres, protein structure known; small spheres, no known protein structure. db, database; eff., efficiency; exp., experimentally; nd, not determined.CC BY-NC-ND · PubMed Central
Fig. 4. THAP11 is part of a functional gene network mediating transcriptional repression of endogenous PARKIN in JumpIN cells. (A) THAP11, HCFC1, and OGT negatively regulate PARK2 mRNA level. PARK2 mRNA level relative to HPRT1 was determined by qPCR on total RNA extracted from stable cell pools of parental JumpIN cells expressing nontargeting (SCR), THAP11- (second strongest sgRNA from screen), HCFC1-, or OGT-specific sgRNAs (strongest sgRNA in screen); n = 3; error bars indicate SDs. **P < 0.01, ***P < 0.001. Average CRISPR/Cas9 editing efficiencies were assessed by TIDE. (B) Targeting of either OGT (Left) or THAP11 (Right) negatively affects endogenous PARKIN protein level. Stable pools of parental cells as in A were analyzed by WB using antibodies indicated. *Nonspecific cross-reaction. CRISPR/Cas9 editing efficiencies were assessed by TIDE. (C and D) Parental cells were infected with THAP11-specific (second strongest sgRNA in screen) or SCR sgRNAs in triplicates for 15 d. Cell extracts were subjected to RNAseq (C), qPCR (D), or WB to assess THAP11 depletion and PARKIN protein elevation (Fig. S4B). In C, transcript fold-changes of THAP11-targeted vs. SCR samples (x-axis, log2) were plotted against P values (y axis, −log10). For hit calling, thresholds were set to <−1 and >1 log2 fold-changes and P < 0.01. The 10 genes most strongly repressed are labeled in blue. PACRG is also repressed by THAP11 (green). (D) qPCR using Taqman probes indicated, scored relative to GAPDH or HPRT1 (PACRG) mRNA, normalized to SCR control. n = 3; error bars indicate SDs. **P < 0.01, ***P < 0.001. (E) Gene-set enrichment analysis suggests modulation of diverse biological processes upon THAP11 depletion. Enrichment analysis for RNAseq using a weighted one-sided Kolmogorov-Smirnov test; test statistic D and negative logarithm (base 10) of adjusted P values are reported. The 10 most enriched sets among up-regulated (Upper) or down-regulated (Lower) transcripts are shown. (F) Comparison of the RNAseq dataset from THAP11-depleted JumpIN cells with data from Poché et al. (29), showing numbers of transcripts regulated by THAP11 in either one or both experiments [cutoff <−1 and >1 fold-changes (log2); P < 0.01]; genes commonly regulated by THAP11 are listed. eff., efficiency; fc, fold-change; ref., reference transcript; rel., relative; WB, Western blot.
Fig. 4. THAP11 is part of a functional gene network mediating transcriptional repression of endogenous PARKIN in JumpIN cells. (A) THAP11, HCFC1, and OGT negatively regulate PARK2 mRNA level. PARK2 mRNA level relative to HPRT1 was determined by qPCR on total RNA extracted from stable cell pools of parental JumpIN cells expressing nontargeting (SCR), THAP11- (second strongest sgRNA from screen), HCFC1-, or OGT-specific sgRNAs (strongest sgRNA in screen); n = 3; error bars indicate SDs. **P < 0.01, ***P < 0.001. Average CRISPR/Cas9 editing efficiencies were assessed by TIDE. (B) Targeting of either OGT (Left) or THAP11 (Right) negatively affects endogenous PARKIN protein level. Stable pools of parental cells as in A were analyzed by WB using antibodies indicated. *Nonspecific cross-reaction. CRISPR/Cas9 editing efficiencies were assessed by TIDE. (C and D) Parental cells were infected with THAP11-specific (second strongest sgRNA in screen) or SCR sgRNAs in triplicates for 15 d. Cell extracts were subjected to RNAseq (C), qPCR (D), or WB to assess THAP11 depletion and PARKIN protein elevation (Fig. S4B). In C, transcript fold-changes of THAP11-targeted vs. SCR samples (x-axis, log2) were plotted against P values (y axis, −log10). For hit calling, thresholds were set to <−1 and >1 log2 fold-changes and P < 0.01. The 10 genes most strongly repressed are labeled in blue. PACRG is also repressed by THAP11 (green). (D) qPCR using Taqman probes indicated, scored relative to GAPDH or HPRT1 (PACRG) mRNA, normalized to SCR control. n = 3; error bars indicate SDs. **P < 0.01, ***P < 0.001. (E) Gene-set enrichment analysis suggests modulation of diverse biological processes upon THAP11 depletion. Enrichment analysis for RNAseq using a weighted one-sided Kolmogorov-Smirnov test; test statistic D and negative logarithm (base 10) of adjusted P values are reported. The 10 most enriched sets among up-regulated (Upper) or down-regulated (Lower) transcripts are shown. (F) Comparison of the RNAseq dataset from THAP11-depleted JumpIN cells with data from Poché et al. (29), showing numbers of transcripts regulated by THAP11 in either one or both experiments [cutoff <−1 and >1 fold-changes (log2); P < 0.01]; genes commonly regulated by THAP11 are listed. eff., efficiency; fc, fold-change; ref., reference transcript; rel., relative; WB, Western blot.CC BY-NC-ND · PubMed Central
Fig. 5. THAP11 modulates endogenous PARKIN abundance and damage-dependent mitophagy priming in endoGFP-PARKIN cells, neuroblastoma cells, and iPSC-derived iNGN2 neurons. (A) Stable pools of endoGFP-PARKIN cells expressing either THAP11-specific (second strongest sgRNA in screen), PARK2-specific, or nontargeting (SCR) sgRNAs were treated with A/O at concentrations shown or DMSO and analyzed at time points indicated by WB using indicated antibodies. *An unspecific cross-reaction of the THAP11 antibody. (B) THAP11 targeting positively affects damage-induced perinuclear pUb accumulation. endoGFP-PARKIN cells expressing THAP11-specific (strongest sgRNA in screen) or SCR sgRNAs for 8 d were treated with A/O or DMSO and analyzed by confocal immunofluorescence microscopy using pUb-specific antibodies (red). Nuclei were Hoechst stained (blue). (C) Extracts from SH-SY5Y Cas9+ cells expressing THAP11-specific (second strongest sgRNA in screen) or SCR sgRNAs for 15 d were analyzed by qPCR using probes indicated (C) or WB using antibodies indicated (D). For C, n = 3; error bars indicate SDs. (E) SH-SY5Y Cas9+ cells expressing sgRNAs as in C and D were treated with A/O or DMSO on day 16 postinfection and analyzed by WB using indicated antibodies. (F–H) iPSC iNGN2 THAP11+/− and iPSC iNGN2 SCR cells were differentiated for 10 d and extracts analyzed by qPCR using Taqman probes indicated (n = 4; error bars indicate SDs; **P < 0.01) (F), or by WB using antibodies indicated (G and H). In H, cells were treated with DMSO or valinomycin 4 h before harvesting. ref., reference transcript; WB, Western blot.
Fig. 5. THAP11 modulates endogenous PARKIN abundance and damage-dependent mitophagy priming in endoGFP-PARKIN cells, neuroblastoma cells, and iPSC-derived iNGN2 neurons. (A) Stable pools of endoGFP-PARKIN cells expressing either THAP11-specific (second strongest sgRNA in screen), PARK2-specific, or nontargeting (SCR) sgRNAs were treated with A/O at concentrations shown or DMSO and analyzed at time points indicated by WB using indicated antibodies. *An unspecific cross-reaction of the THAP11 antibody. (B) THAP11 targeting positively affects damage-induced perinuclear pUb accumulation. endoGFP-PARKIN cells expressing THAP11-specific (strongest sgRNA in screen) or SCR sgRNAs for 8 d were treated with A/O or DMSO and analyzed by confocal immunofluorescence microscopy using pUb-specific antibodies (red). Nuclei were Hoechst stained (blue). (C) Extracts from SH-SY5Y Cas9+ cells expressing THAP11-specific (second strongest sgRNA in screen) or SCR sgRNAs for 15 d were analyzed by qPCR using probes indicated (C) or WB using antibodies indicated (D). For C, n = 3; error bars indicate SDs. (E) SH-SY5Y Cas9+ cells expressing sgRNAs as in C and D were treated with A/O or DMSO on day 16 postinfection and analyzed by WB using indicated antibodies. (F–H) iPSC iNGN2 THAP11+/− and iPSC iNGN2 SCR cells were differentiated for 10 d and extracts analyzed by qPCR using Taqman probes indicated (n = 4; error bars indicate SDs; **P < 0.01) (F), or by WB using antibodies indicated (G and H). In H, cells were treated with DMSO or valinomycin 4 h before harvesting. ref., reference transcript; WB, Western blot.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 100

Metadata

Authors
Potting, C., Crochemore, C., Moretti, F., Nigsch, F., Schmidt, I., Manneville, C., Carbone, W., Knehr, J., DeJesus, R., Lindeman, A., Maher, R., Russ, C., McAllister, G., Reece-Hoyes, J. S., Hoffman, G. R., Roma, G., Müller, M., Sailer, A. W., & Helliwell, S. B.
Affiliations
  • Novartis (Switzerland) (CH)
  • Novartis Institutes for BioMedical Research, Cambridge, MA 02139
  • Novartis Institutes for BioMedical Research, Basel CH 4002, Switzerland;
Corresponding author
Helliwell, Stephen B.
Venue
Proceedings of the National Academy of Sciences
Published
2017-12-21
Volume
115
Issue
2
Pages
E180-E189
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2776435687
Cited by
93
References
63
Citations by year
2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 8 · 2021: 13 · 2020: 20 · 2019: 19 · 2018: 2
FWCI
8.78
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkin, mitophagy, transcriptional repression, Parkinson's disease, mitochondrial damage, autophagy signaling, gene expression regulation, neurons, CRISPR screen
MeSH terms
PTEN-Induced Putative Kinase, Cells, Cultured, Gene Expression Regulation, Humans, Infant, Newborn, Neurons, Phosphorylation, Protein Kinases, Repressor Proteins, Genome, Human, Ubiquitin, Ubiquitin-Protein Ligases, HCT116 Cells, Cell Line, Tumor, Induced Pluripotent Stem Cells, HEK293 Cells, Mitophagy, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy. https://app.cochat.ai/papers/10.1073/pnas.1711023115
The paper
Potting, C., Crochemore, C., Moretti, F., Nigsch, F., Schmidt, I., Manneville, C., Carbone, W., Knehr, J., DeJesus, R., Lindeman, A., Maher, R., Russ, C., McAllister, G., Reece-Hoyes, J. S., Hoffman, G. R., Roma, G., Müller, M., Sailer, A. W., & Helliwell, S. B. (2018). Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1711023115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.